July 25, 2009

Avandia Again Linked with Liver Failure

In the July 22, 2009, edition of the peer-reviewed medical journal Pharmacoepidemiology and Drug Safety researchers identified eleven cases of severe liver toxicity and deaths that were linked to the popular Type 2 diabetes drug Avandia (or rosiglitazone) manufactured by GlaxoSmithKline.  These cases were identified after review of Adverse Event Reports spontaneously submitted to the FDA between 1997 through 2006.  However, many believe that the number of cases identified in the study only represent a small fraction of actual liver failure events due to low reporting submissions to the FDA.  


Since being introduced in 1999, the drug has already been linked to serious health risks including heart attack and heart failure following a May 2007 study published in The New England Journal of Medicine connecting the drug with increased heart attack risk.   In October 2008, increased safety concerns prompted the American Diabetes Association (ADA) and the European Association for the Study of Diabetes to unanimously advise against using Avandia.  Still, approximately three million prescriptions were written for Avandia in 2008.  Several public watch groups including Public Citizen have been imploring that the FDA immediately ban Avandia.


Best Law Firms Badge 2010 Best Law Firms Badge 2011-2012 Best Law Firms Badge 2013 Best Law Firms Badge 2014 Best Law Firms Badge 2015 Listed in Best Lawyers 2015 2015 Legal Leaders - Top Rated Lawyers Best Law Firms Badge 2016 American Board of Trial Advocates
Super Lawyers Badge for C. Todd Alley Super Lawyers Badge for Don Greiwe Super Lawyers Badge for James D. Clark National Board of Trial Advocacy Badge The National Trial Lawyers Badge 2015 Bay Area Legal Sustaining Law Firm
AV Preeminent Badge for James D. Clark AV Preeminent Badge for Donald G. Greiwe AV Preeminent Badge for C. Todd Alley AV Preeminent Badge for Alley, Clark & Greiwe

Contact Us

Alley, Clark & Greiwe

Street Address
201 N. Franklin, 7th Floor,
Tampa, FL 33602

General Email Inquiries:

Call Us 1-813-222-0977

P (813) 222-0977 | F (813) 224-0373

Free Case Evaluation